Midazolam intranasal - OptiNose

Drug Profile

Midazolam intranasal - OptiNose

Alternative Names: Intranasal midazolam spray - OptiNose

Latest Information Update: 04 Apr 2005

Price : $50

At a glance

  • Originator OptiNose AS
  • Developer MedPharm
  • Class Benzodiazepines; Hypnosedatives; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anaesthesia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 31 Mar 2005 Discontinued - Phase-I for Anaesthesia in Norway (Intranasal)
  • 06 Feb 2005 Phase-I clinical trials in Anaesthesia in Norway (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top